UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Double field of view digital sideband holography as an optimized method to measure velocity fields in a large fluid volume

Optics and lasers in engineering, 2024-04, Vol.175, p.107993, Article 107993

2024

Volltextzugriff (PDF)

Factors Predicting Ictal Quality in Bilateral Electroconvulsive Therapy Sessions

Brain sciences, 2021-06, Vol.11 (6), p.781

2021

Volltextzugriff (PDF)

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

The Journal of infectious diseases, 2016-11, Vol.214 (10), p.1512-1519

2016

Volltextzugriff (PDF)

Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study

Current HIV research, 2012-12, Vol.10 (8), p.673

2012

Volltextzugriff (PDF)

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study

Journal of antimicrobial chemotherapy, 2015-04, Vol.70 (4), p.1130-1138

2015

Volltextzugriff (PDF)

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2010-12, Vol.55 (5), p.606

2010

Volltextzugriff (PDF)

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

Journal of antimicrobial chemotherapy, 2015-12, Vol.70 (12), p.3332-3338

2015

Volltextzugriff (PDF)

Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk

Atherosclerosis, 2016-03, Vol.246, p.301-308

2016

Volltextzugriff (PDF)

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

Atherosclerosis, 2012-11, Vol.225 (1), p.200-207

2012

Volltextzugriff (PDF)

Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients

AIDS (London), 2015-05, Vol.29 (8), p.977-979

2015

Volltextzugriff (PDF)

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

Antiviral therapy, 2016-01, Vol.21 (4), p.359-363

2016

Volltextzugriff (PDF)

Maraviroc concentrations in seminal plasma in HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2010-12, Vol.55 (5), p.e35

2010

Volltextzugriff (PDF)

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

Clinical infectious diseases, 2016-06, Vol.62 (12), p.1578-1585

2016

Volltextzugriff (PDF)

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml

Antiviral therapy, 2014-01, Vol.19 (6), p.569-577

2014

Volltextzugriff (PDF)

Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults

AIDS research and human retroviruses, 2011-10, Vol.27 (10), p.1061

2011

Volltextzugriff (PDF)

Estimation of renal allograft half-life: fact or fiction?

Nephrology, dialysis, transplantation, 2011-09, Vol.26 (9), p.3013-3018

2011

Volltextzugriff (PDF)

Short―term and long―term clinical and immunological consequences of stopping antiretroviral therapy in HIV―infected patients with preserved immune function

Antiviral therapy, 2013, Vol.18 (1), p.125-130

2013

Volltextzugriff (PDF)

Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain

The Journal of infection, 2013-02, Vol.66 (2), p.199-201

2013

Volltextzugriff (PDF)

Long‐term fat redistribution in ARV‐naïve HIV+ patients initiating a non‐thymidine containing regimen in clinical practice

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19553-n/a

2014

Volltextzugriff (PDF)

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy

Antiviral therapy, 2012-01, Vol.17 (3), p.577-583

2012

Volltextzugriff (PDF)

Evolution of HIV-1 Genotype in Plasma RNA and Peripheral Blood Mononuclear Cells Proviral Dna after Interruption and Resumption of Antiretroviral Therapy

Antiviral therapy, 2012-04, Vol.17 (3), p.597-597

2012

Volltextzugriff (PDF)

How much fat loss is needed for lipoatrophy to become clinically evident?

AIDS research and human retroviruses, 2009-06, Vol.25 (6), p.563

2009

Volltextzugriff (PDF)

Effectiveness and tolerability of abacavir‐lamivudine‐nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV‐infected, ARV‐naïve patients

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19773-n/a

2014

Volltextzugriff (PDF)

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

HIV clinical trials, 2017-03, Vol.18 (2), p.49-53

2017

Volltextzugriff (PDF)

Analysis of bias stress on thin-film transistors obtained by Hot-Wire Chemical Vapour Deposition

Thin solid films, 2001-02, Vol.383 (1-2), p.307-309

2001

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(54)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Double field of view digital sideband holography as an optimized method to measure velocity fields in a large fluid volume

Factors Predicting Ictal Quality in Bilateral Electroconvulsive Therapy Sessions

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

Maraviroc concentrations in seminal plasma in HIV-infected patients

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml

Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults

Estimation of renal allograft half-life: fact or fiction?

Short―term and long―term clinical and immunological consequences of stopping antiretroviral therapy in HIV―infected patients with preserved immune function

Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain

Long‐term fat redistribution in ARV‐naïve HIV+ patients initiating a non‐thymidine containing regimen in clinical practice

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy

Evolution of HIV-1 Genotype in Plasma RNA and Peripheral Blood Mononuclear Cells Proviral Dna after Interruption and Resumption of Antiretroviral Therapy

How much fat loss is needed for lipoatrophy to become clinically evident?

Effectiveness and tolerability of abacavir‐lamivudine‐nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV‐infected, ARV‐naïve patients

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

Analysis of bias stress on thin-film transistors obtained by Hot-Wire Chemical Vapour Deposition

Suchergebnisse filtern